STING1 and melanoma: Consistent with this paradigm, TLS developed in murine B16 melanomas effectively treated with STING agonist ADU-S100 developed a unique T cell receptor (TCR) repertoire that was not observed in the peripheral T cell population, supporting the operational importance of therapeutic TLS in the melanoma TME.